1. LDLc reduction with fixed-dose combination rosuvastatin-ezetimibe in patients with coronary heart disease that are not candidates for PCSK9 inhibitors treatment. (14th October 2021) Authors: Cordero, A; Escribano, D; Bertomeu-Gonzalez, V; Lopez-Ayala, J M; Monteagudo, M; Quintanilla, A M; Moreno-Arribas, J; Perez-Berbell, P; Zuazola, P Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗